The initial expansion of the glucagon-like peptide-1 (GLP-1) receptor agonist and dual incretin market was defined by a direct-to-consumer distribution race. Early digital health platforms, telehealth prescribers and compounding pharmacies capitalised on immediate consumer demand, focusing heavily on patient acquisition, friction free prescribing and medication fulfilment. However, as the market matures, the fundamental bottleneck has shifted from initial access to long term

The pharmaceutical and clinical landscapes in 2026 are defined by a move away from the management of isolated biomarkers toward a holistic, systems-biology approach to cardiometabolic disease. At the epicentre of this transition are two pharmacological classes that have redefined the expectations of both patients and investors: glucagon-like peptide-1 receptor agonists (GLP-1RAs) and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.